The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma.
Sean P DoyleSaumya S GurbaniAlexandra S RossHavi RosenCharlice Dunn BarrettJeffrey J OlsonHyunsuk ShimHui-Kuo ShuSoma SenguptaPublished in: Oxford medical case reports (2018)
The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considered. In this report, we present such a patient who then received treatment with an epidermal growth factor receptor inhibitor, erlotinib, concurrent with a tumor-treating field device, Optune. Through this combination of a targeted molecular therapy and the Optune device, the patient has been able to achieve stable disease 9 months after completing radiation.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- newly diagnosed
- case report
- high dose
- end stage renal disease
- chronic kidney disease
- ejection fraction
- low dose
- locally advanced
- combination therapy
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- radiation therapy
- mesenchymal stem cells
- replacement therapy
- patient reported
- cell therapy
- chemotherapy induced
- allergic rhinitis